Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -106,13 +106,13 @@
106	106	* US generic sale was Rs. 76 cr. (against Rs. 42 cr.) posting 79% growth.
107	107	* Africa Institution sale was Rs. 46 cr. (against Rs. 63 cr.) posting 26% de-growth.
108	108
109		-**Q4 FY 2019, total export sales were Rs. 343 cr. (against Rs. 348 cr.) posting de-growth of 8%.**
	109	+**12 Months FY 2019, total export sales were Rs. 1,324 cr. (against Rs. 1,434 cr.) posting degrowth of 8%. **
110	110
111		-* Emerging Market branded generic sale was Rs. 221 cr. (against Rs. 243 cr.) posting 1% de-growth. Out of which:
112		-* Africa branded generic sale was Rs. 75 cr. (against Rs. 109 cr.) posting 31% degrowth.
113		-* Asia branded generic sale was Rs. 143 cr. (against Rs. 132 cr.) posting 9% growth.
114		-* US generic sale was Rs. 76 cr. (against Rs. 42 cr.) posting 79% growth.
115		-* Africa Institution sale was Rs. 46 cr. (against Rs. 63 cr.) posting 26% de-growth.
	111	+* Emerging Market branded generic sale was Rs. 846 cr. (against Rs. 856 cr.) posting 1% de-growth. Out of which:
	112	+** Africa branded generic sale was Rs. 307 cr. (against Rs. 355 cr.) posting 14% degrowth.
	113	+** Asia branded generic sale was Rs. 529 cr. (against Rs. 493 cr.) posting 7% growth.
	114	+* US generic sale was Rs. 283 cr. (against Rs. 194 cr.) posting 46% growth.
	115	+* Africa Institution sale was Rs. 196 cr. (against Rs. 384 cr.) posting 49% de-growth.
116	116
117	117	In US, during FY 2019, the company received 10 ANDA final approval; 2 tentative approvals; and filed 13 ANDA with US FDA. Out of 27 final ANDA approvals, Ajanta Pharma has commercialized 25 products. The company hold 2 tentative approvals and 21 ANDAs are awaiting US FDA approval. Company plans to file 10-12 ANDAs during next financial year.
118	118